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The Mitraclip procedure is at present the most widely available method for tran-
scatheter correction of severe mitral regurgitation (MR). The efficacy and the safety 
of the device has been evaluated in the EVEREST II randomized control study1 (head 
to head comparison with traditional surgical repair or replacement of the mitral valve) 
and although not as effective in abolishing MR, it provided significant improvement in 
functional class, along with evidence of favorable ventricular remodeling and with low 
perioperative morbidity and mortality. Currently, over 13.000 implantations have been 
performed worldwide with the number rising steadily. Results from the “real world” 
application of the procedure come from the ACCESS EU registry.2 The procedural 
success (i.e. successful implantation of Mitraclip with reduction in MR to ≤2+) can be 
expected in >95% of cases; 2/3 of patients have functional MR and 1/3 degenerative 
MR; more than 1 clip is required in about 40% of cases and morbidity / mortality are 
fairly low despite the high risk patient population selected for the procedure. Case 
control studies3 suggest that the Mitraclip, in addition to improving quality of life, 
results in a decrease in re-hospitalization rates for heart failure, and may also improve 
survival (compared to medical therapy alone). 
The initial anatomic criteria proposed by the EVEREST II study are well described.1 
In practice though and with expanding experience, operators have ventured and suc-
cessfully treated patients with non-EVEREST anatomies, as for example non-central 
MR jets, left ventricular ejection fraction <25%, end systolic diameter >55 mm.4,5 
The only original EVEREST criterion that appeared to predict unsuccessful result is 
mitral valve area (MVA) <4.0 cm2. In the same study,4 the presence of severe degene-
rative MR also impacted negatively on procedural success (compared to functional 
MR). The number of clips necessary to achieve sufficient MR reduction appears to 
be influenced by the degree of MR as measured by baseline regurgitant volume;6 in 
addition, anatomical factors and in particular increased anterior leaflet thickness also 
appears to be associated with increased odds of implanting two devices.6
In addition, biochemical markers may also predict short and long term outcomes. 
The presence of a decreased eGFR level has been shown to be an independent pre-
dictor of longer hospitalization post MitraClip.7 Advanced heart failure as evidenced 
by an elevated pro-BNP level (≥1600 pg/ml) before the procedure was identified as 
an independent risk factor for mortality at follow up in patients with functional MR.8 
Long term outcomes following Mitraclip depend on achievement of acute proce-
dural success (implant and reduction of MR grade to ≤2+) and on the degree of residual 
MR at discharge from the hospital.9 In addition, it has been shown that a forward 
stroke volume <50 ml (highlighting decreased inotropic reserve of the left ventricle), 
was the most powerful predictor of both rehospitalization and for the composite end 
point of death, rehospitalization and reintervention.4 
INTERVENTIONAL CARDIOLOGY UPDATE
Ygeia Hospital, Athens, Greece




KEY WORDs: mitral valve; mitral 
regurgitation; transcatheter mitral valve 
repair
AbbreviAtions
BNP = brain natriuretic peptide
eGFR = estimated glomerular filtration 
rate
MR = mitral regurgitation
NYHA = New York Heart Association
174
HOSPITAL CHRONICLES 2014, VOLUME 9, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2014»
In aggregate, current studies appear to agree on the safety 
and efficacy of the procedure with significant improvements 
in NYHA functional class, re-hospitalization rates, and left 
ventricular remodeling. Prognostic markers may further help 
in identifying patients most likely to benefit, as well as patients 
that may be too far advanced in the disease process for the 
procedure to make a difference.
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